Indoco Remedies has surged 14% to Rs 187 on BSE after the pharmaceuticals company said it has received a nod from the US Food and Drug Administration (FDA) for two of its facilities in Goa.
The Company has received Establishment Inspection Report (EIR) approving the Company's sterile manufacturing facility (Plant II) and solid dosage manufacturing facility (Plant III) located in Verna, Goa, Indoco Remedies said in a statement.
The company derived 35% of its revenues from exports in 2013-14.
The stock opened at Rs 179 and touched a record high of Rs 197 on BSE. The counter has seen huge trading activity with a combined 782,000 shares changing hands in first 20 minutes of trading on BSE and NSE.
The Company has received Establishment Inspection Report (EIR) approving the Company's sterile manufacturing facility (Plant II) and solid dosage manufacturing facility (Plant III) located in Verna, Goa, Indoco Remedies said in a statement.
The company derived 35% of its revenues from exports in 2013-14.
The stock opened at Rs 179 and touched a record high of Rs 197 on BSE. The counter has seen huge trading activity with a combined 782,000 shares changing hands in first 20 minutes of trading on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%